FCPM III Services B.V.
In its 13F for Q1 2025 (holdings as of March 31, 2025, filed May 15, 2025), FCPM III Services B.V. reported 7 stock positions worth $413.7 million. Its top holding was Newamsterdam Pharma (NAMS) at 54.1% of the portfolio, followed by Dyne Therapeutics (DYN, 13.8%) and Engene (ENGN, 10.4%). Compared with Q4 2024, it sold out of 1, added to 2 and reduced 1. The biggest buy was Newamsterdam Pharma (NAMS, shares +3%) and the biggest sale an exit from Achilles Therapeutics PL-ADR (ACHL).
- Most Recent 13F
- Q2 2026
- Location
- NAARDEN, P7
- CIK
- 0002013410
- Portfolio Value
- $413.7M (Q1 2025)
- SEC Filing
- 0000950123-25-005517 ↗ filed May 15, 2025
Holdings Value
Holdings 7 stocks · $413.7M
| NAMS Newamsterdam Pharma Co. NV | 54.11% | 10,935,310 | $223.8M | Add +3.2% |
| DYN Dyne Therapeutics Inc. | 13.81% | 5,462,846 | $57.1M | No change |
| ENGN Engene Holdings Inc. | 10.43% | 9,632,561 | $43.2M | No change |
| REPL Replimune Group Inc. | 9.21% | 3,909,696 | $38.1M | Reduce -1.5% |
| BCYC Bicycle Therapeutics PLC-ADR | 7.08% | 3,452,330 | $29.3M | No change |
| ATXS Astria Therapeutics Inc. | 4.93% | 3,822,537 | $20.4M | Add +33.1% |
| ENGENE HOLDINGS INC | 0.42% | 2,878,148 | $1.7M | No change |
Portfolio Sells Q4 2024 → Q1 2025
Portfolio Buys Q4 2024 → Q1 2025
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 11 | $750.4M | NAMS, MPLT, DYN, VOR, DMRA |
| Q1 2026 | 10 | $722.2M | NAMS, DYN, VOR, ENGN, MPLT |
| Q4 2025 | 10 | $762.9M | NAMS, DYN, ENGN, RAPT, MPLT |
| Q3 2025 | 9 | $500.4M | NAMS, DYN, ENGN, ATXS, BCYC |
| Q2 2025 | 8 | $369.2M | NAMS, DYN, REPL, ENGN, BCYC |
| Q1 2025 | 7 | $413.7M | NAMS, DYN, ENGN, REPL, BCYC |
| Q4 2024 | 8 | $592.4M | NAMS, DYN, ENGN, BCYC, REPL |
| Q3 2024 | 7 | $582.3M | DYN, NAMS, ENGN, REPL, BCYC |
| Q2 2024 | 7 | $678.1M | DYN, NAMS, ENGN, REPL, BCYC |
| Q1 2024 | 6 | $707.3M | NAMS, DYN, ENGN, REPL, ENGENE HOLDINGS INC |